].
Adenomatous polyposis and hamartomatous polyposis are inherited syndromes that account for 2-5% of all colon cancers. Adenomatous polyposis syndromes include familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MUTYH-associated polyposis (MAP). Hamartomatous polyposis syndromes include Peutz-Jeghers syndrome, juvenile polyposis syndrome, and 'PTEN hamartoma tumor syndrome'. AFAP and MAP, and also Lynch syndrome, can all be associated with only a few adenomas (i.e. 3-10 polyps); nevertheless, each syndrome has distinct cancer risks, characteristic clinical features, and separate genetic etiology. Thus, differential diagnosis is essential for correct management of the specific disease [Lucci-Cordisco et al. 2013] Familial adenomatous polyposis is a hereditary autosomal dominant syndrome that is mainly associated with mutation of the tumor suppressor APC (adenomatous polyposis coli) gene, which is located on chromosome 5q21-q22 [Groden et al. 1991; Kinzler et al. 1991] . FAP is characterized by the onset of hundreds to thousands of adenomas at the level of the large intestine, which usually occurs at a young age. If these are untreated, progress is almost invariably (90%) toward the development of CRC at an average age of 40 years [Vasen et al. 2008] . Patients who carry an APC mutation should undergo colonoscopy every 1-2 years from the age of 10-12 years, and in the presence of adenomatous polyps, they need, instead, annual endoscopic follow up. Prophylactic colectomy is recommended if the polyps are endoscopically untreatable, and proctoscopy should be performed every 6 months, with monitoring for ileum-anal anastomosis every 2 years if total proctocolectomy has been performed [Jasperson et al. 2010] .
Patients with ulcerative colitis and Crohn's disease are associated with high risk of developing CRC. According to a relatively recent meta-analysis, the risk here is estimated at 2%, 8%, and 18% after 10, 20, and 30 years, respectively. The duration and extent of the ulcerative colitis or Crohn's disease are the two most important factors that determine the patient cancer risk. Patients with irritable bowel disease who have a family history of CRC have double the cumulative risk of developing dysplasia, compared with those with a negative history [Eaden et al. 2001 ].
The trend in the incidence of CRC by age follows the typical curve of the majority of cancers, increasing with age. Indeed, CRC diagnoses are sporadic in the younger age groups, while the frequencies are of the order of 50 cases per 100,000 inhabitants/year between 30-50 years, which increases to 100 cases between 50-70 years, and reaching about 250 cases at ages >70 years. The incidence rates are similar between the two sexes up to the age of 45 years; however, the curve for males then shows a steeper increase and reaches higher values.
Surgery is the mainstay of treatment for early colorectal tumors. Colon cancers are treated by surgical excision and with complete mesocolic excision [Hohenberger et al. 2009; Sehgal and Coffey 2014 ] which appears to be as appropriate as total mesorectal excision for rectal cancer. These allow excellent oncological outcome, with a 5-year cancer-specific survival rate of 91.4% in stage II, and 70.2% in stage III [Siani and Pulica, 2014] . In the case of obstruction, perforation, and bleeding, emergency segmental colectomy for resection of the tumor is indicated [Sagar, 2011] . Several international multicenter randomized trials have shown that minimally invasive surgery is a safe and valid alternative to open surgery, with less postoperative pain, shorter duration of hospital stay, and similar oncological outcomes. Robotic surgery has not been shown to be better for either colon or rectal cancer, compared with an adequate laparoscopic approach [Tyler et al. 2013; Baek et al. 2013 ].
The staging of rectal cancer is crucial to define the most appropriate treatment strategy, with some important factors defined here, such as distance from the anal verge, circumferential margin, nodal stage, and vascular and nerve invasion. Local excision can be considered for very early tumors (i.e. stage 1) and for malignant polyps with an invasion level of '0-3'; this should also be supported by accurate preoperative diagnosis with endorectal ultrasound, magnetic resonance imaging, and computed tomography scanning. A transanal procedure as a video-assisted technique can be performed, with either transanal endoscopic microsurgery [Sgourakis et al. 2011; Guerrieri et al. 2014] or transanal minimally invasive surgery [Matz and Matz, 2012; Atallah et al. 2010 ]. In the more advanced disease stages, surgery with total mesorectal excision is the appropriate procedure, either performed laparoscopically or as open surgery. Neoadjuvant chemoradiotherapy is indicated in locally-advanced rectal cancer, to reduce local recurrence rates. This became standard practice after the publication of the results of the German CAO/ARO/AIO-94 randomized phase III trial [Sauer et al. 2012 ]. Long-course chemoradiation and short-course radiation can both be considered here [Sauer et al. 2012; Schmoll et al. 2012 ]. Infusional 5-fluorouracil has been commonly used in neoadjuvant treatment, although the oral capecitabine appears to be equally effective and more manageable [Hofheinz et al. 2012 ].
Stage IV disease (i.e. CRC with metastatic sites, mCRC) is commonly treated with chemotherapy, with several drugs used in combination with 5-fluorouracil and leucovorin (e.g. oxaliplatin-FOLFOX, irinotecan-FOLFIRI). There are two monoclonal antibodies against the epidermal growth factor receptor (EGFR) that are now commercially available (i.e. cetuximab and panitumumab) [Downward 2003 ], and these are used in combination with commonly used treatment schedules [Tveit et al. 2012; Peeters et al. 2010; van Cutsem et al. 2009 ]. The National Cancer Institute of Canada Clinical Trials Group CO.17 trial demonstrated that the anti-EGFR monoclonal antibody cetuximab improves overall survival (OS) and progression-free survival (PFS) in patients with advanced, chemotherapy-refractory CRC, particularly in patients with wild-type KRAS tumors [Au et al. 2009 ].
These therapies show very low objective response rates because of the high Ras/Raf mutation rates in CRC [Bazan et al. 2002] . Biological chemotherapy also includes the vascular endothelial growth factor (VEGF)-A-targeted antibodies bevacizumab and aflibercept, recombinant proteins that target VEGF-A, VEGF-B, and placental growth factor (PlGF), and these have been approved by the US Food and Drug Administration for mCRC, in combination with standard cytotoxic chemotherapy [Ciombor et al. 2015; Hurwitz et al. 2004; van Cutsem et al. 2012; Tabernero et al. 2014] . New therapeutic agents in the targeting of the EGFR and VEGF receptor (VEGFR) pathways, and those targeting other signal-transduction pathways, such as the MET, IGF1R, MEK, phosphoinositide 3-kinase (PI3K), Wnt, Notch, Hedgehog, and death-receptor signaling pathways, are now under evaluation for the treatment of mCRC [Seow et al. 2016] .
Some groups claim that regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, has an important role in the prevention of CRC; according to some studies, these can reduce the risk by 40% [Cuzick et al. 2009 ]. Furthermore, randomized studies have evaluated the preventive effects of aspirin on the development of adenomatous polyps, with reports of an inverse association between use of NSAIDs and incidence of CRC [Bosetti et al. 2006 [Bosetti et al. , 2009 Chan et al. 2005; Dubé et al. 2007] . Although numerous studies have shown preventive effects of aspirin on incidence and size of adenomatous polyps [Gann et al. 1993; Baron et al. 2003; Benamouzig et al. 2003; Chan et al. 2004] , the dose and duration of treatment have never been specified, and some studies have failed to demonstrate effects of aspirin on the incidence of any specific cancer [Cook et al. 2005 ]. More randomized trials are mandatory to clarify the real preventive role of aspirin in CRC.
Model for colorectal cancer tumorigenesis
The development of CRC is characterized by the 'adenoma-carcinoma sequence'. Thus, the normal epithelium acquires sequential genetic and epigenetic mutations in specific oncogenes or tumor suppressor genes, becomes a hyperproliferative mucosa, and later gives rise to a benign adenoma that changes into a carcinoma and metastases over an average of 10 years ( Figure 1 ) [Pancione et al. 2012; Ewing et al. 2014; Vogelstein et al. 1988] .
Normal gastrointestinal epithelium is organized along a crypt-villus axis. At the bottom of the crypts, there is a pool of colon stem cells and progenitor cells, which are the most undifferentiated cell types that can undergo self-renewal and show pluripotency. These cells can move along the crypt-villus axis while differentiating into all of the epithelial colon lineages, such as Paneth cells, goblet cells, enterocytes, and enteroendocrine cells. In about 14 days, they arrive at the top of the villus, and undergo programmed cell death by apoptosis [Peifer, 2002; Kosinski et al. 2007 ]. This process is orchestrated by gradients of proteins, such as Wnt, bone morphogenetic protein (BMP) and transforming growth factor (TGF)-β, together with the extracellular matrix and stromal cells that form the cell niches [Medema and Vermeulen, 2011] .
The stem cell niches thus have a critical role in the maintenance of stem cell properties, by providing them with protection from differentiation and apoptosis, and through controlling their turnover [Moore and Lemischka, 2006; Medema and Vermeulen, 2011] . It has been suggested that these stem cells are involved in cancer onset and progression, through their acquiring tumorigenic potential, and thus transforming into cancer stem cells (CSCs). These CSCs represent the only tumor cells that can initiate cancer transformation, progression, and metastases, and they are probably responsible both for relapse and resistance to therapy [Gangemi et al. 2009; Fanali et al. 2014 ]. The source from which CSCs arise is still unclear. It remains a topic for discussion whether differentiated cancer cells can de-differentiate, and thus transform into CSCs, or alternatively, whether healthy stem cells accumulate genetic mutations that confer them a neoplastic phenotype [O'Brien et al. 2007; Greaves and Maley, 2012] . Moreover, in contrast to the clonal hypothesis that was formulated to explain the mechanisms responsible for cancer onset and progression, the CSC hypothesis is a hierarchical theory according to which only a few undifferentiated cells, the CSCs, can promote tumor onset, progression, and metastases [Puglisi et al. 2009 ]. In agreement with this hypothesis, tumors should be composed mainly of differentiated cancer cells and of a few undifferentiated CSCs, which although slowly duplicating, are the only cells that Several factors, such as growth factors and genetic or epigenetic alterations in specific oncogenes or tumor suppressor genes, confer a selective advantage to epithelial cells for proliferation and self-renewal. The normal epithelium becomes a hyperproliferative mucosa and subsequently gives rise to a benign adenoma, which can then evolve into a carcinoma and metastases. Different genetic changes characterize colorectal cancer progression in tumors with microsatellite instability and chromosomal instability. Alterations in genes involved in epithelial to mesenchymal transition, basal membrane degradation, cell adhesion, and angiogenesis are finally responsible for metastasis development. CIN, chromosomal instability; CIMP, CpG island methylator phenotype; MSI, microsatellite instability; APC, adenomatous polyposis coli; KRAS, Kirsten Rat Sarcoma viral oncogene homolog; TP53, Tumor Protein 53; PI3K, Phosphoinositide 3 Kinase; TGFBRII, Transforming Growth Factor Beta Receptor II; PTEN, Phosphatase and Tensin homolog; SMAD4-DCC, Small Mother Against Decapentaplegic 4-Deleted in Colorectal Carcinoma; c-MET, Mesenchymal to Epithelial Transition factor; ZEB-1, Zinc finger E-box Binding homeobox-1; MMP, Matrix Metalloproteinase; TIMP-1, Tissue Inhibitor of Metalloproteinase-1; uPAR, urokinase-type Plasminogen Activator Receptor; CD44, Cluster of Differentiation 44; CEA, Carcinoembryonic Antigen; VEGF, Vascular Endothelial Growth Factor; PD-ECGF, Platelet Derived-Endothelial Cell Growth Factor; B-RAF, v-raf murine sarcoma viral oncogene homolog B1; BAX, Bcl2-Associated X protein; IGF-1, Insulin Growth Factor-1; EGFR, Epidermal Growth Factor Receptor; COX2, Cyclooxigenase 2; HGF, Hepatocyte Growth Factor; PDGF, Platelet Derived Growth Factor; TGF-B, Transforming Growth Factor Beta; VEGF, Vascular Endothelial Growth Factor.
can undergo self-renewal and show multipotency [Vermeulen et al. 2008 ].
It has been demonstrated recently that during epithelial to mesenchymal transition (EMT), epithelial cancer cells acquire not only mesenchymal traits, but also a stem cell-like phenotype, with the ability for self-renewal, unlimited proliferation, and resistance to apoptosis. This observation suggests that EMT might represent a tumor source of undifferentiated cancer cells, as the CSCs or stem celllike cells [Dallas et al. 2009; Fan et al. 2012] . EMT consists of an essential phenotypic conversion of epithelial cells into cells with a mesenchymal phenotype. It is a reversible process that often occurs during embryonic development and tissue remodeling, and it also has a critical role in the early events that occur in invasion and metastases of many types of cancer, including CRC [Batlle et al. 2000 ]. EMT regulation is orchestrated through a group of transcription factors, including Snail, Slug, ZEB1 and Twist, although the tumor microenvironment also has a role in this conversion through different signals, such as TGF-β, EGF, Wnt and Notch [Cano et al. 2000; Li et al. 2014 ].
During EMT, epithelial cells lose E-cadherin expression, which specifically guarantees the epithelial phenotype, with destruction of their intercellular adhesion, and acquisition of mesenchymal characteristics and increased migratory and invasive properties [Thiery et al. 2009 ]. Furthermore, the EMT program induces stem cell-specific gene expression, thus promoting the self-renewal capability [Mani et al. 2008] .
Metastases are the first cause of death in CRC, as well as with many other solid tumors, and this defines stage IV CRC, which is characterized by relatively short OS [Singh and Settleman, 2010] . During metastases development, the cells acquire the ability to invade the basal membrane that divides the epithelial tissues from the extracellular matrix, and they migrate into surrounding tissues. Later, they join the endothelial cells from lymphatic and blood vessels and arrive in the lumen, in a process known as intravasation. Subsequently, the cells that survive in the lumen of the vessels come out from the vases (i.e. extravasation), disseminate into the adjacent organs, and finally colonize them to generate micrometastases, Thus, as described above, EMT confers to the epithelial cells the traits that are needed to enable them to complete this process [Singh and Settleman, 2010; Thiery et al. 2009 ].
Molecular heterogeneity of colorectal cancer
At the molecular level, CRCs are a very heterogeneous group of diseases, and this appears to have a critical role in the generation of drug resistance, and ultimately, in the mechanism of relapse. Loss of genomic integrity facilitates accumulation of multiple mutations during the development of CRC. Chromosomal instability, microsatellite instability (MSI), aberrant DNA methylation (i.e. the CpG island methylator phenotype), and DNA repair defects are all mechanisms that are involved in colorectal epithelial cell transformation, and they all have a significant role in CRCs ( Figure 1 ) [Goel et al. 2007; Sideris and Papagrigoriadis, 2014; Pino and Chung, 2010; Boland and Goel, 2010; Colussi et al. 2013] . It is well accepted that a tumor is classified as positive in terms of the CpG island methylator phenotype if it shows methylation of at least three of the following markers: CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 [Cohen et al. 2016] .
Chromosomal instability arises in about 60% of CRCs, and this is a phenomenon that is related to the presence of abnormal chromosome numbers or complements [Pino and Chung, 2010] . MSI is caused by alterations to DNA MMR mechanisms, and it consists of variations in the numbers of repetitive units in each microsatellite sequence. MSI is a characteristic of patients with Lynch syndrome, although it is also associated with about 15-22% of sporadic CRCs [Corso et al. 2013 ]. Inactivation of the MMR genes (i.e. MLH1, MSH2, MSH6, PMS1, PMS2) through deletions, point mutations, or epigenetic silencing [Aaltonen et al. 1993; Ionov et al. 1993; Thibodeau et al. 1993; Vasen et al. 1999 ] is responsible for MSI, which causes the failure of the DNA MMR system to repair errors that occur during replication. On the basis of the observed degree of instability, it has been possible to distinguish two well defined MSI phenotypes in particular: MSI-high (MSI-H) and MSI-low (MSI-L; or microsatellite stable, MSS) [Boland and Goel. 2010; Colussi et al. 2013] .
Tumor cells with an MSI-positive phenotype accumulate mutations consequent to the defective DNA repair mechanism, and this might activate key oncogenes or inactivate tumor suppressor genes. The TGF-β tumor suppressor gene [Markowitz et al. 1995] , the TGF-β type II receptor (TGF-βR2), BAX, caspase 5 apoptotic regulators [Duval and Hamelin, 2002; Vousden and Prives, 2009] , and the tumor suppressor gene TCF4 (which has been implicated in deregulation of the Wnt/β-catenin/TCF signaling pathway) are the most frequently altered genes in these tumors [Cuilliere-Dartigues et al. 2006 ].
The mechanism of MMR gene inactivation is different between sporadic and hereditary cancers. The most frequent MMR gene alteration in sporadic CRCs consists of promoter hypermethylation of the hMLH1 gene, instead of point mutations of the hMLH1 or hMSH2 genes, as described for HNPCC [Markowitz and Bertagnolli, 2009 ]. The MSI sporadic CRCs are frequently associated with the BRAF V600E mutation, which mediates extensive epigenetic silencing in CRC [Fang et al. 2016 ]. This Each molecular signaling pathway represents a target for precision therapy, and specific proteins can be used as predictive molecular biomarkers that are essential in the characterization of colorectal cancer as a disease, for determination of personalized care. Approved biological chemotherapies are boxed in red. The Wnt signaling pathway regulates β-catenin concentrations, which finally activate specific target genes, together with members of LEF/ TCF. Ras is a multi-tasking protein that interacts with several effectors. The first Ras effector pathway identified was the Raf-MEK-ERK pathway. Ras/Raf signaling results in mitogen-activated protein kinase activation, which are a group of serine/ threonine kinases that mediate signal transduction from the plasma membrane to the nucleus in response to several extracellular stimulations, such as growth factors and mitogenic factors. The second best-characterized target of Ras signaling is the PI3K pathway, which is an essential player in the Ras-mediated cell survival and proliferation. Changes in PI3K signaling represent one of the most frequent events in human cancers, as well as in colon cancer. It is well known that three tyrosine kinase pathways can activate the PI3K proteins, and in particular, the Ras protein can interact and activate several PI3K proteins. PTEN is a negative regulator of PI3K, with roles in the dephosphorylation and down-regulation of PIP3 levels. The SRC/FAK pathway, the STAT3 pathway, the PI3K/ AKT pathway, and the Ras pathways are all cMET target pathways [Cooper et al. 1984; Birchmeir et al. 2003 ]. On the other hand, cMET is mainly regulated by HIF-1α, the expression of which is stimulated by hypoxia therefore represents a diagnostic marker to distinguish sporadic from hereditary CRC [Capper et al. 2013] .
Several altered molecular signaling pathways are involved in CRC onset, such as the Wnt, RAS/ MAPK, PI3K, TGF-β, NF-κB pathways or DNA MMR genes. These alterations are responsible for responsiveness or resistance to antitumor agents ( Figure 2 ), and they can confer individual susceptibility to cancers when they are germlines [Markowitz and Bertagnolli, 2009; Najdi et al. 2011; De Rosa et al. 2015] .
Activating mutations of the Ras gene and pathway, including alterations of many of its regulators or effectors, probably represent the most frequent genetic alterations in human tumors [Bos, 1989; Rojas and Santos, 2002; Parsons et al. 2005; Mandal et al. 2015; Moura et al. 2015; Ratner and Miller, 2015] . Ras is a multitasking protein that cooperates with several effectors in the regulation of many cellular processes, such as cell proliferation, differentiation, apoptosis, and senescence [Moodie et al. 1993; Warne et al. 1993; Hallberg et al. 1994; ] . The Ras genes (i.e. K-, H-and NRas) are localized on chromosomes 12, 11 and 1, respectively, and encode small proteins with GTPase activity that associate with the plasma membrane.
Ras mutations usually activate Ras signaling by enhancing GTP levels, and in this way mediating phosphorylation and activation of the Raf proteins (A, B and C) ( Figure 2 ) [Vojtek et al. 1993; Zhang et al. 1993; Malumbres and Barbacid, 2003] . It is now believed that oncogenic Ras can promote tumor onset and progression [Chin et al. 1999] , although multiple Ras-interacting proteins, such as the PI3Ks, appear to be required to sustain tumor growth [Lim and Counter, 2005] . For example, oncogenic Ras and PI3K cooperate to promote the loss of anoikis, so taking part in the progression of an advanced tumor into metastases [Chiarugi and Giannoni, 2008; Simpson et al. 2008] .
The PI3K pathway is often dysfunctional in both sporadic and hereditary CRC, and it activates cell growth, inhibits apoptosis, and regulates cellular transformation, adhesion, motility, and survival [Cantley, 2002; Fruman et al. 1998 ] in response to several extracellular signals, such as growth factors, cytokines, hormones, heat and oxidative stress, hypoxia, and hypoglycemia ( Figure 2 ) [Testa and Bellacosa, 2001; Martini et al. 2014; Vivanco and Sawyers, 2002; Castellano and Downward, 2011] .
Several genes and alternative splicing mechanisms are responsible for the synthesis of the PI3K heterodimeric lipid kinases complex, which consists of the catalytic, adaptor and regulatory subunits. This protein family has three main classes (class I, II, and III), with class I as the best characterized and the most clearly known to be associated with human cancers [Yuan and Cantley, 2008; Castellano and Downward, 2011] . The main reported alterations are recurrent mutations in the PIK3CA gene [Engelman et al. 2006; Samuels et al. 2004] , such as gene amplifications, deletions, and somatic missense mutations, which probably increase the kinase activity of PIK3CA, to contribute to cellular transformation [Karakas et al. 2006 ].
PTEN is a negative regulator of the PI3K/AKT pathway ( Figure 2 ), and is a tumor suppressor gene, alterations to which are involved in several sporadic and hereditary CRCs. As with small quantitative alterations of PTEN expression, somatic mutations in the PTEN gene have been shown to be associated with different kinds of cancers [Eng 2003; Manfredi 2010] .
The hepatocyte growth factor (HGF) receptor is known as mesenchymal-epithelial transition factor (cMET), and it belongs to the tyrosine kinase receptor super-family. The cMET binds its ligand, HGF, which leads to its dimerization, phosphorylation, and finally, activation ( Figure 2 ). The cMET proto-oncogene, which is encoded by 21 exons, and is localized on chromosome 7 at position q21-q31 [Duh et al. 1997; Liu, 1998 ]. This activation of the HGF/cMET pathway induces EMT, with the regulation of specific mechanisms, such as E/Ncadherin switching and extracellular matrix degradation processes. These, in turn, promote cell motility, survival, and proliferation. It is now well known that EMT is a physiological cellular mechanism that tumor cells borrow during the metastatic process. In this way, in many human cancers, the HGF/cMET pathway participates in malignant progression and cell scattering, invasion, and protection from apoptosis, and in metastasis formation [Fujita and Sugano, 1997; Samamé Pérez-Vargas et al. 2013; Smith and Bhowmick, 2016] .
Several mechanisms are involved in this cMET activation, and many human cancers have been described with point mutations, gene amplification, mRNA overexpression, or ligand autocrine loops [Samamé Pérez-Vargas et al. 2013] . Another way by which the HGF/cMET signaling pathway contributes to tumor progression and metastases is through stimulation of angiogenesis and lymphangiogenesis, thus acting in a synergistic manner with the VEGF/VEGFR pathway ( Figure 2) . Moreover, the HGF/cMET signaling pathway promotes the growth of endothelial cells and overexpression of pro-angiogenic factors, such as VEGF itself [Ding et al. 2003; Zhang et al. 2003; Matsumura et al. 2013 ].
The role of angiogenesis in tumor progression and metastases has been well investigated for a long time. The mammalian VEGF family consists of five glycoproteins (i.e. VEGFA, VEGFB, VEGFC, VEGFD, PlGF), among which VEGFA is the best characterized [Dvorak, 2002; Hicklin and Ellis, 2005; Fan et al. 2005] . In-vitro studies have shown that a monoclonal antibody against VEGFR1 blocks tumor cell migration and invasion in CRC cells that overexpress this receptor [Ellis and Hicklin, 2008] . The VEGFR is a tyrosine kinase protein that binds its ligand and activates downstream signaling pathways that promote pro-angiogenic processes (Figure 2 ) [Kowanetz and Ferrara, 2006] . A role for VEGF was also recently suggested in the escape of tumors from immune responses, through the block of dendritic cell differentiation [Gabrilovich et al. 1996; Ohm et al. 2003; Ellis and Hicklin, 2008] . Indeed, dendritic cells are antigen-presenting cells that have a critical role in presenting cancer antigens to several immune cell types [Steinman et al. 2003; Banchereau and Palucka, 2005; Colonna et al. 2006 ].
The microenvironment is mainly represented by the immune system and the extracellular matrix, and it also provides tumor heterogeneity [Vermeulen et al. 2010; Herrera et al. 2013; Berdiel-Acer et al. 2014] . In both localized tumors and the whole organism, the interactions between normal and tumor cells contribute to inter-individual genetic heterogeneity. These interactions are the reason for the different responses between individuals with apparently similar tumors, which are due to their different genetic backgrounds.
Colorectal cancer heterogeneity can be observed among antitumor immune surveillance systems, mainly in terms of the major histocompatibility complex, although this heterogeneity is also seen for other important molecules that are dedicated to immunological regulation, such as galectin-3 and programmed death ligand-1 [Bernal et al. 2011] . There is now strong evidence that subcellular populations showing CD3+, CD8+, and CD45RO+ antigens have a central role in antitumor immunological responses. Altered expression of major histocompatibility complex antigens represents an early event in CRC tumorigenesis. This induces the so-called phase of 'escape', in which clones of tumor cells can evade the immunological control and initiate metastatic spreading [Garrido et al. 1993 [Garrido et al. , 1997 . Interestingly, the presence of peritumoral inflammatory infiltrate is a characteristic of MSI tumors that correlates with a good prognosis. This confirms that tumor immunological characteristics and responses in CRC are related to the genetic background of the tumor [Sinicrope and Sargent, 2012] .
As described above, during EMT, the cancer cells can detach from the primary cancer, migrate into the surrounding tissues, and start the metastatic development that is characterized by intravasation, dissemination, extravasation, and colonization. Thus, once in the vessels, these cancer cells can circulate in the blood. CRCs show great heterogeneity not only in the primary tumor, but also in these circulating cancer cells. Indeed, they show different differentiation grades and epithelial, mesenchymal, or stem cell biomarker expression [Yu et al. 2013] . Investigations into the molecular biomarkers of these circulating cancer cells represent an interesting field in CRC clinical research. The cancer cells that show mesenchymal and stem cell-like phenotypes are more able to undergo extravasation and colonization of distant organs, compared with those with an epithelial phenotype [Tsai and Yang, 2013; Kalikaki et al. 2014 ].
As described above, CRCs are characterized by this great genotypic and phenotypic heterogeneity that includes the tumor microenvironment and the interactions between healthy and cancer cells. All of these traits confer unique peculiarities to each tumor, and thus each tumor can be considered as a single disease. Here, well conducted molecular and clinical characterization is essential, with the view to implement precision oncology, and thus personalized care.
Prognostic and predictive biomarkers in colorectal cancer
Prognostic and predictive biomarkers for cancer predisposition Molecular characterization of inherited CRCs allows presymptomatic diagnosis to identify at-risk individuals, and thus improves cancer surveillance. Differential diagnosis can be very difficult between syndromes because of their phenotypic variability. Attenuated FAP, MAP and Lynch syndrome can all be associated with only a few adenomas (e.g. 3-10 polyps); nevertheless, each syndrome has distinct cancer risks, characteristic clinical features, and separate genetic etiology. Differential diagnosis is also essential for suitable patient management of hamartomatous polyposis syndromes, because each of these syndromes has its own characteristic organ-specific manifestations, and each requires a precise surveillance approach. According to the literature, we suggest that next-generation sequencing (NGS) is at present the best and most efficient technique for molecular diagnosis of hereditary colorectal polyposis syndrome, hereditary colorectal cancer, and familial colorectal cancer. Indeed, NGS allows a number of different genes associated with colon cancer to be considered for differential diagnosis, which include APC, MUTYH, PTEN, STK11, BMPR1A, SMAD4, MLH1, MSH2, MSH6, PMS2, CDH1, CHEK2, EPCAM, TP53, and other genes related to these molecular signaling pathways. This approach allows the detection of previously unidentified low-frequency allelic variants, including novel candidate loci.
Prognostic and predictive pathological biomarkers
Personalized patient care is one of the main goals of research in oncology. The aim here is the standardization of therapeutic plans designed and chosen according to the genetic background of each specific neoplasm, in order to increase OS and reduce treatment side effects. Thus, prognostic and predictive molecular biomarkers assume a critical role in characterization of the disease and in determination of the most appropriate therapy. Prognostic biomarkers improve the characterization of the disease, while predictive biomarkers allow the prediction of the likely response to therapy, and also the potential disease outcome.
To date, tumor node metastases (TNM) staging still represents the 'gold standard' for tumor classification, and it offers valuable prognostic information and a guide to the necessary therapy decisions. However, the relationship between the TNM stage and patient prognosis is very complex, because each cancer stage is also a heterogeneous group [Gunderson et al. 2010] , and indeed, stage II patients who do not receive postoperative adjuvant chemotherapy sometimes show the same disease outcome as stage III patients.
Taking into account these considerations, other biomarkers will be useful for combination with the TNM classification for the prediction of responses to therapy and for the planning of personalized care.
Tumor budding is defined as the presence of a single tumor cell or a group of up to five such cells that have detached at the invasive tumor front and have broken off from the main tumor body. These then 'blend' into the tumor microenvironment, as the classical peritumoral budding, or remain inside the tumor, known as intratumoral budding [Prall, 2007; Komori et al. 2010; Zlobec et al. 2014; Ueno et al. 2002] . These cells represent tumor cells that have undergone EMT [Dawson and Lugli, 2015; Attramadal et al. 2015] , and according to their mesenchymal characteristics, they also show hypoproliferative status and resistance to apoptosis and anoikis [Dawson et al. 2014; Guadamillas et al. 2011] . As expected, high grades of tumor buds are associated with high grades of neo-angiogenesis, lymph-node infiltration, and distant metastases, and therefore, poor patient prognosis [Ishikawa et al. 2008; Nakamura et al. 2005; Wang et al. 2009 ]. Tumor budding is now considered to be a useful predictive marker of node positivity in patients who are pTN0 [Park et al. 2005; Choi et al. 2009; Tateishi et al. 2010] or have early pT1-2 disease; no difference in survival has been reported between patients who are pTN0 and show high-grade tumor budding and patients who are pTN positive Okuyama et al. 2003 ]. However, tumor budding has also been suggested as a marker to select patients with adenoma or early T1 disease who will need complete resection after endoscopic resection, including the lymph nodes [Yasuda et al. 2007] .
Given the feature of these tumor cells invading the tumor microenvironment, it can often be difficult to distinguish these from peritumoral cells, and thus on this basis, pan cytokeratin detection might represent a useful marker to allow precise cytological characterization [Horcic et al. 2013] . At the molecular level, tumor budding is more represented in APC-mutated tumors than in microsatellite-unstable tumors. Nevertheless, in both of these, tumor budding is a marker for poor patient prognosis [Jass et al. 2003; Zlobec et al. 2012] . However, there is cross-talk between invading tumor cells, as seen by peritumoral budding, and immune defender cells; indeed, the negative effects of tumor budding are mitigated by the presence of immune cells [Zlobec et al. 2011] , which suggests that each prognostic biomarker needs to be interpreted in the context of the tumor heterogeneity. Thus, as discussed above, tumor budding represents a strong marker that is useful for precise tumor classification and that needs to be improved in the near future, initially with the definition of an internationally accepted scoring system.
As cancer outcome is the result of several factors that particularly involve the immune system, a novel prognostic index has been developed, which has been defined as the 'immunoscore'. This is based on the lymphocyte populations at the tumor invasive front. Specifically, the CD3+/CD45RO+, CD3+/CD8+, or CD8+/CD45RO+ cell concentrations can be converted into a score that lies between I-0 and I-4. There is strong correlation between the immunoscore and tumor outcome, such that a higher immunoscore is associated with improved prognosis. As with tumor budding, the immunoscore has also been shown to be more helpful toward better tumor classification than the TNM alone, and thus it has been suggested that the immunoscore should be included as part of the TNM staging system, to generate the TNM-Immunoscore (TNM-I) system [Galon et al. 2014; Mlecnik et al. 2011; Broussard and Disis, 2011; Blanco-Calvo et al. 2015] .
Prognostic and predictive molecular biomarkers As indicated above, MSI status has been classically classified into two or three groups: MSI-H, as tumors that show instability in ⩾30% of the microsatellites analyzed; MSI-L, which defines tumors that show 10-30% as unstable microsatellites; and MSS tumors, with stable microsatellites [Lee and Chan, 2011; Jass 2007 ]. More rarely, MSI has been divided into positive or negative, with MSI-L and MSS considered as a unique group [Domingo et al. 2013; Simons et al. 2013; Hagland et al. 2013] . A panel of five mononucleotide markers (i.e. is currently being used by most clinical laboratories to detect MSI.
The role of MSI as a prognostic biomarker has been well demonstrated. A retrospective finding confirmed by the Pan-European Trials in Adjuvant Colon Cancer III (PETACC III) trial showed better relapse-free survival and OS, and decreased risk of metastases, for MSI-H tumors, compared with MSI-L and MSS, independent of the disease grade [Marisa et al. 2013; Sideris and Papagrigoriadis, 2014] . Moreover MSI tumors show particular clinicopathological features, including their location in the proximal colon, and an increased cancer onset age with poor or mucinous differentiation [Church et al. 2012; Domingo et al. 2013; Hagland et al. 2013] , lymphocytic infiltration, and an inflammatory reaction [De Smedt et al. 2015] . Thus, the advanced stage of MSI-H tumors resembles the early stage of MSI-L and MSS tumors [Erstad et al. 2015] .
The prognostic role of MSI for the prediction of response to therapy is still controversial. Several reports have described the relationship between MSI-H status and worse response to 5-fluorouracil, compared with that obtained for MSI-L and MSS tumors [Webber et al. 2015; Kawakami et al. 2015] . However, there are also several findings that are not in agreement, and a definitive answer is awaited [Erstad et al. 2015] .
As indicated above, the Ras proto-oncogene acts downstream of EGFR and has as its major targets the RAF-MEK-ERK and PI3K pathways. A mutation in the KRAS gene represents an early event in colorectal tumorigenesis, which is associated with more than 40% of patients with CRC. Hot-spot mutations located at codons 12, 13, 61, and 143 account for about 97% of the known CRC-associated mutations [http://www.sanger. ac.uk/genetics/CGP/cosmic].
At present, EGFR and VEGFR inhibitors represent the only approved biological drugs for mCRC, which can be combined with traditional chemotherapy [Esin and Yalcin, 2016; Goldstein et al. 2015] . Thus, studies concerning alterations in all of the genes and pathways related to EGFR, such as K-, H-, and NRAS, BRAF, PI3KCA and PTEN, have become of great interest in clinical cancer research. Moreover, only KRAS mutations have been validated and are accepted in clinical practice as predictive biomarkers of response to EGFR inhibitors.
Several studies over the last decade, starting with the CO.17 (KRAS Mutations and Benefit From Cetuximab in Advanced Colorectal Cancer) trial, have provided evidence that not all KRAS mutations interfere equally with patient responses to EGFR monoclonal antibodies. However, tumors carrying a G13D mutation have better PFS and OS when classical chemotherapy is combined with cetuximab, compared with tumors with all of the other KRAS mutations or with wild-type KRAS treated without cetuximab [Karapetis et al. 2008; De Roock et al. 2010a , 2010b Tejpar et al. 2011 Tejpar et al. , 2012 Osumi et al. 2015] . Then, the two clinically available agents of cetuximab and panitumumab became the standard third-line treatment as monotherapies for chemotherapyrefractory patients with mCRC. Furthermore, mutations in codons 12 and 13 of the KRAS gene confer the same resistance when patients are treated with panitumumab in addition to chemotherapy, as FOLOFOX4 or FOLFIRI [Amado et al. 2008; Peeters et al. 2010; Peeters et al. 2013; Taieb et al. 2016] .
Recently, Rowland and colleagues conducted the first systematic review and meta-analysis of eight randomized controlled trials that evaluated the impact of KRAS G13D on survival benefit of anti-EGFR monoclonal antibody therapy. This study highlighted that the efficacy of anti-EGFR monoclonal antibody therapy does not differ significantly between KRAS G13D and other KRAS mutations in mCRC tumors, whereas it confirmed that significant PFS and OS benefits were observed for patients with KRAS wild-type tumors [Rowland et al. 2016 ].
The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Among Patients with a G13D Mutation) study was the first prospective study to evaluate the efficacy of cetuximab alone or in combination with irinotecan in patients with quadruple wild-type KRAS, NRAS, BRAF, and PI3KCA mCRC and with tumors with KRAS G13D mutations. The results of this study were recently reported by Segelov and colleagues [Segelov et al. 2016] and confirmed the findings of Rowland and colleagues [Rowland et al. 2016] by demonstrating that in patients with KRAS G13D-mutated chemotherapy-refractory mCRC there was no statistically significant improvement in disease with either cetuximab monotherapy or cetuximab plus irinotecan. No responses were seen with single-agent cetuximab, although a modest response was seen with the combination of cetuximab and irinotecan, which might reflect drug synergy or persistent irinotecan sensitivity [Segelov et al. 2016] . KRAS codon 61 and 146 mutations have been described as having roles in reducing PFS, but not OS, in patients with mCRC treated with cetuximab in addition to classical chemotherapy De Roock et al. 2010a ].
In a retrospective analysis, De Roock and colleagues suggested that patients with G13Dmutated tumors had worse OS than those with wild-type KRAS tumors and those with tumors bearing other KRAS mutations, however this poor prognosis was mitigated by cetuximab treatment. [De Roock et al. 2010b ]. The potential prognostic role of KRAS mutations remains unclear. In mCRC, it is difficult to distinguish KRAS effects on patient survival from its effect on patient response to therapy [Garassino et al. 2008 ]. However, ambiguous data have also been obtained from patients with nonmetastatic CRC [Roth et al. 2010; Hutchins et al. 2011] .
BRAF is a serine-threonine kinase that is phosphorylated and activated by KRAS. BRAF mutations, which are mutually exclusive to KRAS mutations, are frequently found in solid tumors, and specifically in sporadic CRC, with a frequency of around 8-10%. The V600E mutation represents a hotspot mutation that when present, locks the cell in a constitutively active status of the Ras/ RAF/MEK/ERK pathway, in a manner similar to KRAS mutations [Di Nicolantonio et al. 2008 ]. BRAF represents a better prognostic than predictive biomarker. Colorectal tumors with BRAF mutations benefit less from anti-EGFR therapy than do wild-type BRAF tumors. However, the resistance of BRAF-mutated tumors to EGFR inhibitors is still controversial [De Stefano and Carlomagno, 2014; Benvenuti et al. 2007; Haraldsdottir and Bekaii-Saab, 2013] . Moreover, BRAF mutation is often associated with sporadic MSI-H CRC and a sessile/ serrated adenoma sequence, and so it can be considered a diagnostic biomarker that can be used to distinguish hereditary from sporadic MSI-H tumors [van Lier et al. 2010; Sideris and Papagrigoriadis, 2014] . The role of BRAF mutation as a prognostic biomarker depends on the combination with other genetic alterations. Indeed, BRAF mutations are associated with poor prognosis in MSS and MSI-L CRC, but their known effect is reduced for MSI-H status [Roth et al. 2010; Pai et al. 2012; Ogino et al. 2012; de Cuba et al. 2016 ].
Neuroblastoma-RAS (NRAS) is a member of the RAS family that encodes proteins with GTPase activities. The NRAS gene is located on chromosome 1, and its mutations that occur in about 3-5% of sporadic CRC [De Roock et al. 2010b] are mutually exclusive to KRAS and BRAF mutations [Hawkes and Cunningham, 2010] . It is already clear that NRAS mutations also confer resistance to EGFR inhibitors [De Roock et al. 2010b ]. Thus, according to all of the issues discussed here, mutational analysis of the RAS genes is recommended to better identify patients who can benefit from therapies with EGFR inhibitors.
PIK3CA encodes the catalytic subunit of the PI3K enzyme [Lai et al. 2015] . Mutations in this gene occur in about 10-20% of patients with sporadic CRC, whereby two hotspot mutations located in exons 9 and 20 account for about 80% of all mutations found to date. In a RAS wild-type tumor, PIK3CA mutations have been suggested to cause resistance to anti-EGFR treatment, although this finding is still under discussion [de la Rochefordiere et al. 2015] . Furthermore, the relevance of PIK3CA mutations as predictive biomarkers appears to be connected to the response to aspirin in patients with CRC. There have been several studies that have suggested that only when a tumor carries a PIK3CA mutation do the patients have a longer OS when aspirin is regularly used [Liao et al. 2012; Ogino et al. 2012 ].
The phosphatase and tensin homologue (PTEN) gene is frequently altered in human sporadic and inherited cancers, according to several mechanisms, including gene mutations, allelic losses, and promoter hypermethylation. This last epigenetic alteration is a characteristic of MSI-H CRC, as it occurs in about 19% of these tumors [Lin et al. 2015] , whereas about 20% of unselected tumors show loss of the PTEN protein, as determined by immunohistochemistry assays [Sartore-Bianchi et al. 2009 ]. In contrast to RAS and BRAF mutations, PTEN and RAS mutations are not mutually exclusive events. Recent studies have shown that PTEN mutations can have roles in resistance to cetuximab or panitumumab, and that PTEN promoter methylation and mutation status might be useful as a predictive biomarker for responses to anti-EGFR therapies [Therkildsen et al. 2014; Lupini et al. 2015; Sood et al. 2012] .
Recently, the evaluation of the 'Quadruple index' has been proposed, which associates the probability of EGFR monoclonal antibody responses with changes in one of the following genes: KRAS, BRAF, PIK3CA and PTEN. This study showed that 70% of CRCs show one alteration at most. Furthermore, the presence of only one mutation gives a response probability of about 5%, which then becomes 0% in a tumor carrier with two changes. Tumors without mutations in these genes have about 51% possibility of responding to these therapies [Sartore-Bianchi et al. 2009 Therkildsen et al. 2014 ].
Angiogenesis represents another critical mechanism in tumor formation and it is thus a target for biological therapy. Although the use of anti-angiogenic drugs is growing in clinical practice for patients with advanced CRC, there are no validated biomarkers that can be used to predict the response to anti-angiogenic drugs [Jubb and Harris, 2010; Jayson et al. 2011] . In the AVF107 pivotal study, the relationships between all of the VEGF proteins and receptors and their responses to bevacizumab were investigated. This suggested that VEGF-D expression might represent a good predictive biomarker for anti-angiogenic response, with high expression of the VEGF-D protein associated with longer PFS and OS than seen for tumors with low expression of VEGF-D. Another trial demonstrated an association between high expression of CD31, VEGF-A, and EGFR-2 and benefit from bevacizumab-including regimens [Luo and Xu, 2014] . Moreover, hypertension is a common side effect of anti-angiogenic therapy, and thus has been suggested as a predictive biomarker to reveal a favorable response; however, this issue deserves further investigation [Tahover et al. 2013] . Although there are no validated predictive biomarkers relating to the use of anti-angiogenic drugs, VEGF has a prognostic value: high VEGF expression is associated to poor prognosis for patients with CRC, low response to preoperative radiotherapy, and relapses. Instead, VEGF-C has been suggested to be a prognostic biomarker in rectal cancer [Yin et al. 2013 ].
The hepatocyte growth factor receptor is a threonine kinase receptor that has been suggested to be useful in the prediction of responses to cetuximab combined therapies. Some studies have reported recently that overexpression of cMET is associated with shorter median PFS and OS, compared with tumors that express normal or low levels of cMET [Sadanandam et al. 2013] . Another threonine kinase receptor that appears to have a role as a prognostic and predictive biomarker is insulin-like receptor 1 (IGF1R). This is a transmembrane receptor that is overexpressed in about 50-90% of all CRCs [Koda et al. 2004; Takahari et al. 2009 ], and preclinical studies have shown that its overexpression is correlated with poor prognosis and bad responses to EGFR inhibitors in several tumor types Choi et al. 2015] .
Prognostic and predictive stemness biomarkers
According to the hierarchical model of cancer onset, CSCs are the only cancer cells that can initiate neoplastic transformation, progression and metastases, and they are probably responsible for resistance to therapy and for relapse [Doherty et al. 2016] . The EMT mechanism also has a role in these processes, as it appears to represent a source of CSCs or to confer motility to epithelial cancer cells through their interconversion into a mesenchymal subtype [Pietilä et al. 2016] . One of the first molecular biomarkers associated with cancer stemness was CD133. It later became clear that, instead, the CD133 protein is expressed both in differentiated and undifferentiated cancer cells, and that there is no exclusive relationship between its expression and cancer cell stemness, selfrenewal, and tumorigenicity, nor tumor progression and patient survival [Lugli et al. 2010] . Other biomarkers, such as CD29, CD44, EpCAM, CD166, ALDH1A1 and ALDH1B1, are now considered to be linked to stemness and also to cancer stage, differentiation, invasiveness and metastases [Lugli et al. 2010; Zeuner et al. 2014] .
CD44 is a transmembrane glycoprotein that interacts with components of the extracellular matrix, such as hyaluronic acid, and it is present in cells in several isoforms that arise from alternative splicing mechanisms. CD44 is a target of the Wnt/ β-catenin signaling pathway, and it has been considered for a long time as a marker of cancer stemness [Ozawa et al. 2014; Lugli et al. 2010] . Although CD44 knockdown reduces cancer aggressiveness in colon cancer in vitro and in vivo, it is probable that only the CD44v6 alternative isoforms represent a specific colon cancer stem cell marker that is useful for the recognition of cells that can invade the surrounding tissues and initiate the cancer metastasis process [Subramaniam et al. 2010; Kemper et al. 2010; Todaro et al. 2014] .
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that has a role in epithelial cell-cell adhesion, and also takes part in cell migration, proliferation and differentiation [Patriarca et al. 2012] . It has been suggested that EpCAM is a diagnostic marker because its overexpression has been associated with advanced cancer stages and shortened median OS for patients with colon and rectal cancer Goossens-Beumer et al. 2014 ].
Activated leukocyte cell adhesion molecule (ALCAM), which is also known as CD166 (cluster of differentiation 166), is implicated in cell adhesion and migration. Multiple alternatively-spliced transcript variants encode different isoforms. ALCAM expression is very variable in CRC tissues; moreover, its overexpression has been associated with shortened OS and poor patient prognosis. The use of ALCAM to identify a CD44+/EpCAM+ subpopulation of cancer cells has also been suggested [Lugli et al. 2010; Tachezy et al. 2012; Langan et al. 2012] .
CD24 is a sialoglycoprotein that modulates cell growth and differentiation signals. As such, it has been described as being associated with cell differentiation, lymph node metastases, and shortened OS [Lim and Oh, 2005; Seo et al. 2015] .
Aldehyde dehydrogenase is the subsequent enzyme after alcohol dehydrogenase in the major pathway of alcohol metabolism, the overexpression of which has been associated with the stemness of several epithelial cell types, such as breast, stomach, and colon [Deng et al. 2010 ]. The literature data show that high ALDH1 expression is associated with high tumor grade and bad prognosis of disease [Langan et al. 2012; Chen et al 2015] .
The leucine-rich-repeat-containing G-proteincoupled receptor 5 (Lgr5) gene encodes the R-spondin receptor, which is an agonist of the canonical Wnt pathway, and has been described to be responsible for maintenance of stemness in adult intestinal epithelial cells. It has been suggested that Lgr5-positive cancer cells might be adult stem cells that become CSCs in tumors [Barker et al. 2007 ]. Recently, high LGR5 expression has been reported in CRC-invading cells, which was characterized by high CD44 and low KRT20 expression, combined with a remarkable increase in the stem cell population [Baker et al. 2015] . In CRC, high LGR5 protein expression has also been associated with high risk of relapse, decrease of disease-free survival, and high rate of hepatic and lymph node metastases [Jiang et al. 2016] .
As indicated by these details above, a statistically validated profile of CSCs and other prognostic markers would be expected to provide a better and more comprehensive assessment of the patient susceptibility to metastatic disease than any single molecular marker.
Schölch and colleagues developed an orthotopic mouse model of CRC that reproduces the process of CRC dissemination. Circulating tumor cells (CTCs) derived from this model showed stem cell-like characteristics and formed colonies in vitro and tumors in vivo. This study has provided new insight into the biology of CRC-derived CTCs, and it might provide new therapeutic targets in mCRC [Schölch et al. 2016] . Also recently, Ong and colleagues showed that expression of the stem-like group of markers (i.e. CD44, LGR5, SOX2, OCT4) was associated with significantly worse patient prognosis compared with cases with their lower expression. Furthermore, patients with high levels of these stem-like markers showed greater benefit from adjuvant treatments than other patients. The biologically diagnostic/ prognostic relevance of these stem-like markers was also observed in early stage I cancers, which suggests a potential opportunity for identification of aggressive tumors at a very early stage of the disease, as well as the identification of the small subgroup of patients who will derive benefit from adjuvant chemotherapy following surgery [Ong et al. 2015] .
Taking these findings together, we suggest that stem cell marker expression should be investigated further, together with EMT cell biomarkers (e.g. vimentin, Twist-1, Snail, Slug, Zeb-1), with a view to the definition of their role in therapeutic decision-making. Furthermore, in agreement with the opinion of the scientific community, we believe that the CSC hypothesis opens interesting perspectives for cancer diagnosis and care, because specific factors associated with CSC and EMT appear to represent the best diagnostic, prognostic and therapeutic targets for patients with CRC.
Circulating biomarkers
Despite progress in the knowledge of the molecular basis of CRC onset and progression, and also the efforts to identify new prognostic/ predictive peripheral biomarkers, the only two blood biomarkers available to monitor patients with CRC are carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). CEA is a highmolecular-weight glycoprotein that is specific to embryonic tissue and is also found in colorectal malignancies. At the moment, it represents the antigen that is used in clinical practice as a prognostic marker to follow disease progression after diagnosis, as the CA19-9 antigen is less sensitive and specific for CRC compared with CEA [Locker et al. 2006 ].
There is evidence that the presence and percentage of CTCs in the blood correlate with disease status and are associated with progression of cancer and metastatic disease. It would thus be useful to monitor advanced disease in cases that do not show overexpression of other circulating cancer biomarkers, such as CEA or CA19-9 [Cohen et al. 2008 ]. Detection of cancer-specific mutations in CTCs will fulfill a controversial role as a diagnostic/ prognostic factor, because the cancer mutation panel needs to be known at diagnosis. However, methylation analysis of specific genes, such as Vimentin, NGFR, SEPT9, and TMEFF2, and also p16, APC, hMLH1, HLTF, and DAPK, has been under evaluation [Li et al. 2009 ]. It has been reported that SEPT9 methylation detects CRC with 70% sensitivity and 90% specificity, and a PCR-based assay to identify SEPT9 methylation is now commercially available as a kit (Epi proColon Early Detection Assay, Epigenomics, Germany) [deVos et al. 2009 ].
To date, CSC panels of multiplexed predictive molecular biomarkers should be used in the new age of liquid biopsies for solid tumors. However, all candidate circulating CRC-specific markers need to be further validated in large, randomized trials to determine their clinical utility in screening for CRC.
Conclusion
As described so far, several alterations at the molecular level favor CRC onset and progression, and the formation of metastases. Thus, molecular characterization of cancer-associated mutations can provide valuable information on disease prognosis and patient response to therapy. The advent of NGS technology has allowed better, more rapid, and also cheaper, molecular characterization of cancers, and clinically-relevant biomarkers can be measured. In summary, germline mutational screening of genes responsible for hereditary and familial CRC represent essential molecular tests for cancer predisposition, while several somatic predictive/ prognostic molecular biomarkers are available today. As described above, KRAS mutations are the only molecular marker actually validated and accepted in clinical practice as a predictive biomarker in response to EGFR inhibition. However, the 'Quadruple index', which associates EGFR monoclonal antibody responses with changes in one or more of four genes, as KRAS, BRAF, PIK3CA and PTEN, might provide further information. The MSI status has a role as a prognostic biomarker, although its role as a predictive biomarker for response to therapy remains to be clarified. In our opinion, the TNM-I system coupled with tumor budding might represent the best pathological prognostic biomarkers, which need to be validated for clinical practice. Furthermore, stemness and EMT molecular biomarkers might not only improve cancer screening and early detection, but might also help to define the best postsurgery follow up, not only for patients with advanced and mCRC, but also for patients with early stage disease, such as node-negative patients. Only stem cells have the potential for unlimited proliferation, multi-lineage differentiation, and colonization of new sites, and thus these represent the most likely precursors for invasive and mCRC, and therefore these CSCs require much further attention.
As we have previously reported, a multidisciplinary approach that includes genetics, molecular biology, surgery, and clinical oncology is the only way to achieve the best results for patient outcomes [De Rosa et al. 2015] . On this issue, future studies in CRC need to be concentrated on the standardization of procedures to better determine the genetic profile of each cancer and to define a panel of predictive/ prognostic biomarkers that will allow surgeons and clinical oncologist to choose the best treatment strategy for each, and every single patient. colorectal cancer patients, whereas codon 12 K-RAS mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446.
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